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S18 Diabetic Nephropathywith diabetic nephropathy and investigate the relationship between
glucagon like peptide-1 receptor agonist and the expression of COX2 in renal
medulla.
Methods: 130 male Sprague Dawley rats were divided into the conventional
feed group (normal group, n Z 30) and high sugar and fat diet fed group
(nZ 100) randomly. Diabetic rats were induced by intraperitoneal injection
of streptozotocin after high sugar and fat diets fed eight weeks. The diabetic
rats (nZ 72) divided into the diabetic nephropathy (DN) group, Low-Liraglu-
tide (L-Lg, 5 mg/kg) group and High-Liraglutide (H-Lg, 10 mg/kg) group. To
measure the blood pressure, the level of sodium, 24-hour urinary sodium
(UNa) and 24-hour urinary 6-keto-prostaglandin F1a (6k-PGF1a). Determina-
tion of the expression of COX2 in renal medullary tissue using immunohisto-
chemistry. Using Western blot technology analysis the expression of COX2
protein in the renal medullary.
Results: Compared with N Group, the blood pressure, the serum sodium and
UNa are increasing, the urinary 6k-PGF1a is decreasing, the renal medulla
expression of COX2 is increasing in DN group (P < 0.05). Compared with
the DN group, the blood pressure, the serum sodium and UNa are decreasing,
the urinary 6k-PGF1a is increasing, the renal medulla expression of COX2 is
still increasing in L-Lg group and H-Lg group (P < 0.05). Compared with L-Lg
group, the renal medulla expression of COX2 is further increasing (P < 0.05).
Conclusion: GLP-1 receptor agonist Liraglutide can reduce the blood pres-
sure, the serum sodium, increase the excretion of 24-hour urinary sodium
excretion in DN rats, and increase the excretion of 24-hour urinary 6k-
PGF1a, and upregulate the expression of COX2 protein in the renal medulla.
The mechanism of GLP-1 receptor agonist regulate blood pressure and wa-
ter-sodium metabolism by activation of COX2.http://dx.doi.org/10.1016/j.hkjn.2015.08.053
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Objective: Compare the efficacy and safety of anticoagulation with
different doses of heparin in the continuous renal replacement therapy
(CRRT) for diabetic nephropathy, confirm the effective dose of anticoagu-
lant in the treatment of CRRT for diabetic nephropathy to provide the basic
data for clinical work.
Methods: 54 patients with diabetic nephropathy were randomly divided into
three groups; group 1 (18 patients, heparin, 0.3 mg/kg), group 2 (18 pa-
tients, heparin, 0.4 mg/kg), group 3 (18 patients, heparin, 0.5 mg/kg). To
evaluate coagulation function, the filter and pipeline were observed; the
activated partial thromboplastin time (APTT) and platelet levels were moni-
tored before or after treatment.
Results: In group 1, the APTT and platelet levels had no significant change
after treatment; in group 2, the APTT extended to 1.5 times with no signif-
icant change of platelet levels; in group 3, the APTT raised obviously, other-
wise, the platelet levels decreased remarkable with significance among
group 1, group 2 and group 3 (P < 0.05).
Conclusion: As for diabetic nephropathy, a larger dose of heparin could in-
crease efficacy and safety of CRRT.http://dx.doi.org/10.1016/j.hkjn.2015.08.054
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Downregulation of the Expression of PINCH-1 in Kidney Tissue by
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Objective: To investigate the effect of irbesartan in regulating the expres-
sion of PINCH-1 in the kidney tissue of diabetes mellitus rat using diabetes
mellitus rat model.
Methods: After establishing rat model of diabetes mellitus, real-time poly-
merase chain reaction (RT-PCR) and Western blot were applied to detect
the expression of PINC-1 in the kidney tissue of diabetes mellitus rat after
irbesartan treatment.Results: RT-PCR shown the PINCH-1 mRNA expression in diabetes mellitus rat
(1.537  0.04) was higher than in the normal rat (1.128  0.03), and
decreased after the treatment of irbesartan (1.246  0.02) (P < 0.05). West-
ern blot showed the expression of PINCH-1 in the kidney tissue of diabetes
mellitus rat with irbesartan treatment (1.159  0.03) (P > 0.05).
Conclusion: Irbesartan could downregulate the expression of PINCH-1 in the
kidney tissue of diabetes mellitus rat.http://dx.doi.org/10.1016/j.hkjn.2015.08.055
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Objective: To analyze the kidney pathogenesis of proteinuria in patients
with type 2 diabetes mellitus.
Methods: Selected 50 cases of type 2 diabetic patients with proteinuria,
all of which were given tests as follows, echocardiography, carotid ultra-
sonography, fundus examination, glomerular filtration rate, renal func-
tion, blood lipids, blood glucose, glycosylated hemoglobin, urine
analysis, 24 hour urinary protein quantitative clinical physical examination
and renal biopsy. According to the pathological results, patients were
divided into diabetic nephropathy group and non-diabetic nephropathy
group.
Results: 48.2% of 50 cases were diagnosed as diabetic nephropathy, while
51.8% were diabetic patients with other glomerular diseases, namely non-
diabetic nephropathy, and in which the highest proportion was focal
segmental glomerulosclerosis. Fasting blood glucose was high in diabetic
nephropathy group (P < 0.05). Cardiac color Doppler ultrasound indicated
that the ejection fraction in the diabetic nephropathy group was signifi-
cantly lower than that in the non-diabetic nephropathy group
(P < 0.05). Carotid artery ultrasonography examination showed that in
diabetic nephropathy group The number of atherosclerotic plaque pa-
tients was significantly higher than that in non-diabetic nephropathy
group, while the intima media thickness (IMT) of the carotid artery in dia-
betic nephropathy group was higher than that in non-diabetic nephropathy
group (P < 0.05). It is worth noting that the non-diabetic nephropathy has
little to do with diabetic retinopathy, which means diabetic retinopathy
has a high sensitivity and specificity for the diagnosis of diabetic nephrop-
athy (P < 0.01).
Conclusion: in the case of type 2 diabetes complicated with urinary protein,
fasting blood glucose, heart shot ejection fraction, carotid atheromatous
plaque and intima-media thickness, and fundus changes could be used as
thereference indexes for the diagnosis of diabetic nephropathy and non-dia-
betic nephropathy, while renal biopsy is an important diagnosis index of dia-
betic kidney disease.http://dx.doi.org/10.1016/j.hkjn.2015.08.056
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Objectives: To evaluate the new pathological classification of diabetic
nephropathy (DN) published by Research Committee of the
Renal Pathology Society in 2010 and to investigate clinical and patholog-
ical predictors of tubulointerstitial injury in new pathological
classification.
Methods: 43 cases with DN performed renal biopsy. Patients were
divided into different groups according to glomerular classification
or interstitial fibrosis and tubular atrophy (IFTA) score by the new
pathological classification. We used X2 test or Fisher’s exact test, Mann-
Whitney U-test, Kruskal-Wallis H-test and Spearman’s correlation to make
comparisons and correlations between the clinical and pathological findings
